Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 361–372 of 411 articles
- Explore study findings
What an MRI showed about liver fat in SYNCHRONIZE-MASLD
Survodutide is an investigational glucagon and GLP-1 receptor agonist peptide. A phase 3 study reported in 2026 asked whether it changed liver fat and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD.
Survodutide2 sources (2024, 2026)
- Understand the science
How SYNCHRONIZE-1 counted average weight change and response rates
Survodutide is an investigational peptide that activates GLP-1 and glucagon receptors. SYNCHRONIZE-1 tested it in adults with obesity or overweight and a related complication who did not have diabetes.
Survodutide1 source (2026)
- Explore study findings
Why the earlier MASH trial examined liver tissue directly
Survodutide is an investigational peptide with activity at the glucagon and GLP-1 receptors. The older direct study for the biopsy question was a phase 2 trial in adults with confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and varying degrees of scarring.
Survodutide2 sources (2024, 2026)
- Explore study findings
Why a two-amino-acid breakdown product drew attention in 2026
TB-500 is used here for the acetylated seven-amino-acid fragment corresponding to part of thymosin beta-4. A 2026 study asked whether a smaller molecule made during its breakdown could explain some effects attributed to the parent peptide.
TB-5002 sources (2024, 2026)
- Explore study findings
What a rat Achilles study reported for its TB-500 group
TB-500 commonly refers to a synthetic acetylated fragment of thymosin beta-4 made from seven amino acids. A July 2026 rat experiment used a reagent labeled TB-500 after surgical repair of the Achilles tendon.
TB-5002 sources (2012, 2026)
- Explore study findings
Which molecule the 2026 HHS policy calls TB-500
Department of Health and Human Services defined TB-500 acetate as the acetate form of an N-acetylated seven-amino-acid fragment of thymosin beta-4. The policy makes the chemical identity explicit because names used for research products can be ambiguous.
TB-5003 sources (2026)
- Check methods and identity
What mass spectrometry detected as TB-500 broke down
TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4. In an older 2024 study, researchers asked which shorter molecules appeared after it was broken down and whether those molecules could be measured separately.
TB-5002 sources (2024, 2026)
- Understand the science
How a laboratory identified the acetylated fragment
TB-500 can refer to a short acetylated fragment of thymosin beta-4. The name became associated with that identity in part through an older 2012 study of a product sold under the name. The scientists used high-resolution mass spectrometry to examine the material.
TB-5001 source (2012)
- Understand the science
How to read a human eye trial cited alongside TB-500
TB-500 generally refers to an acetylated seven-amino-acid fragment related to thymosin beta-4. An older human trial often discussed in the same research area investigated a specific eye formulation, RGN-259, whose active substance was synthetic full-length thymosin beta-4.
TB-5002 sources (2012, 2015)
- Check methods and identity
What the current U.S. label means by excess abdominal fat
Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat?
Tesamorelin2 sources (2010, 2026)
- Check methods and identity
What the TRIUMPH trial is designed to measure about physical function
Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone.
Tesamorelin2 sources (2026)
- Check methods and identity
What bioequivalence means in a comparison of tesamorelin formulations
Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults.
Tesamorelin2 sources (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
